California Public Employees Retirement System lowered its position in shares of Emergent Biosolutions, Inc. (NYSE:EBS) by 8.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 45,800 shares of the biopharmaceutical company’s stock after selling 4,400 shares during the period. California Public Employees Retirement System owned 0.11% of Emergent Biosolutions worth $1,330,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. State of Alaska Department of Revenue raised its position in shares of Emergent Biosolutions by 2.7% in the first quarter. State of Alaska Department of Revenue now owns 3,820 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 100 shares during the period. Municipal Employees Retirement System of Michigan raised its position in shares of Emergent Biosolutions by 1.7% in the first quarter. Municipal Employees Retirement System of Michigan now owns 10,720 shares of the biopharmaceutical company’s stock worth $312,000 after buying an additional 180 shares during the period. Louisiana State Employees Retirement System raised its position in shares of Emergent Biosolutions by 2.2% in the first quarter. Louisiana State Employees Retirement System now owns 14,100 shares of the biopharmaceutical company’s stock worth $409,000 after buying an additional 300 shares during the period. Arizona State Retirement System raised its position in shares of Emergent Biosolutions by 1.7% in the first quarter. Arizona State Retirement System now owns 18,060 shares of the biopharmaceutical company’s stock worth $524,000 after buying an additional 300 shares during the period. Finally, Bank of Montreal Can raised its position in shares of Emergent Biosolutions by 0.4% in the first quarter. Bank of Montreal Can now owns 113,198 shares of the biopharmaceutical company’s stock worth $3,288,000 after buying an additional 473 shares during the period. 85.48% of the stock is currently owned by institutional investors.

Emergent Biosolutions, Inc. (EBS) opened at 36.155 on Tuesday. The firm has a market capitalization of $1.48 billion, a price-to-earnings ratio of 28.740 and a beta of 1.22. The company’s 50-day moving average price is $34.24 and its 200-day moving average price is $31.22. Emergent Biosolutions, Inc. has a 12-month low of $24.47 and a 12-month high of $36.81.

Emergent Biosolutions (NYSE:EBS) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $0.13 EPS for the quarter, missing analysts’ consensus estimates of $0.26 by $0.13. The business had revenue of $100.77 million during the quarter, compared to analyst estimates of $111.57 million. Emergent Biosolutions had a return on equity of 14.50% and a net margin of 13.42%. Emergent Biosolutions’s revenue for the quarter was up 10.4% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.05) EPS. Equities analysts expect that Emergent Biosolutions, Inc. will post $1.56 EPS for the current fiscal year.

WARNING: “Emergent Biosolutions, Inc. (EBS) Shares Sold by California Public Employees Retirement System” was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another domain, it was stolen and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.dailypolitical.com/2017/08/08/emergent-biosolutions-inc-ebs-shares-sold-by-california-public-employees-retirement-system.html.

A number of research analysts have recently commented on the company. BidaskClub lowered Emergent Biosolutions from a “buy” rating to a “hold” rating in a report on Friday. Zacks Investment Research lowered Emergent Biosolutions from a “hold” rating to a “sell” rating in a report on Monday, July 17th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $44.00.

In other Emergent Biosolutions news, Chairman Fuad El-Hibri sold 25,000 shares of the business’s stock in a transaction on Thursday, July 27th. The stock was sold at an average price of $36.50, for a total value of $912,500.00. Following the transaction, the chairman now owns 1,630,216 shares of the company’s stock, valued at $59,502,884. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 16.50% of the stock is currently owned by insiders.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Institutional Ownership by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.